{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:34:37Z","timestamp":1787027677978,"version":"build-2736575974"},"reference-count":33,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T00:00:00Z","timestamp":1665792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Charles University","award":["260529"],"award-info":[{"award-number":["260529"]}]},{"name":"Charles University","award":["PROGRES Q34"],"award-info":[{"award-number":["PROGRES Q34"]}]},{"name":"Charles University","award":["207035"],"award-info":[{"award-number":["207035"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>The goal of the study was to establish an efficient first-trimester predictive model for any type of preterm birth before 37 gestational weeks (spontaneous preterm birth (PTB) or preterm prelabor rupture of membranes (PPROM)) in the absence of other pregnancy-related complications, such as gestational hypertension, preeclampsia, fetal growth restriction, or small for gestational age. The retrospective study was performed in the period from 11\/2012 to 3\/2020. Peripheral blood samples were collected from 6440 Caucasian individuals involving 41 PTB and 65 PPROM singleton pregnancies. A control group with 80 singleton term pregnancies was selected on the basis of equal sample-storage time. A combination of only six microRNAs (miR-16-5p, miR-21-5p, miR-24-3p, miR-133a-3p, miR-155-5p, and miR-210-3p; AUC 0.812, p &lt; 0.001, 70.75% sensitivity, 78.75% specificity, cut-off &gt; 0.652) could predict preterm delivery before 37 gestational weeks in early stages of gestation in 52.83% of pregnancies with a 10.0% FPR. This predictive model for preterm birth based on aberrant microRNA expression profile was further improved via implementation of maternal clinical characteristics (maternal age and BMI at early stages of gestation, infertility treatment with assisted reproductive technology, occurrence of preterm delivery before 37 gestational weeks in previous pregnancy(ies), and presence of any kind of autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, type 1 diabetes mellitus, or other autoimmune disease)). With this model, 69.81% of pregnancies destined to deliver before 37 gestational weeks were identified with a 10.0% FPR at early stages of gestation. When other clinical variables as well as those mentioned above\u2014such as positive first-trimester screening for early preeclampsia with onset before 34 gestational weeks and\/or fetal growth restriction with onset before 37 gestational weeks using the Fetal Medicine Foundation algorithm, as well as positive first-trimester screening for spontaneous preterm birth with onset before 34 gestational weeks using the Fetal Medicine Foundation algorithm\u2014were added to the predictive model for preterm birth, the predictive power was even slightly increased to 71.70% with a 10.0% FPR. Nevertheless, we prefer to keep the first-trimester screening for any type of preterm birth occurring before 37 gestational weeks in the absence of other pregnancy-related complications as simple as possible.<\/jats:p>","DOI":"10.3390\/biomedicines10102591","type":"journal-article","created":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T21:10:10Z","timestamp":1665954610000},"page":"2591","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel First-Trimester Prediction Model for Any Type of Preterm Birth Occurring before 37 Gestational Weeks in the Absence of Other Pregnancy-Related Complications Based on Cardiovascular Disease-Associated MicroRNAs and Basic Maternal Clinical Characteristics"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4396-3304","authenticated-orcid":false,"given":"Ilona","family":"Hromadnikova","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Cell Pathology, Third Faculty of Medicine, Charles University, 10000 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Kotlabova","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Cell Pathology, Third Faculty of Medicine, Charles University, 10000 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Krofta","sequence":"additional","affiliation":[{"name":"Institute for the Care of the Mother and Child, Third Faculty of Medicine, Charles University, 14700 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0140-6736(08)60074-4","article-title":"Epidemiology and causes of preterm birth","volume":"371","author":"Goldenberg","year":"2008","journal-title":"Lancet"},{"key":"ref_2","first-page":"571","article-title":"Preterm prevention: Effectivenss of current strategies","volume":"18","author":"Moutquin","year":"1996","journal-title":"J. Soc. Obstet. Gynaecol. Can."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1471-0528.2006.01120.x","article-title":"The preterm parturition syndrome","volume":"113","author":"Romero","year":"2006","journal-title":"BJOG"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/pd.2662","article-title":"Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11\u201313 weeks","volume":"31","author":"Beta","year":"2011","journal-title":"Prenat. Diagn."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/uog.17455","article-title":"Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11\u201313 weeks\u2019 gestation: Comparison with NI-CE guidelines and ACOG recommendations","volume":"49","author":"Wright","year":"2017","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103.e1","DOI":"10.1016\/j.ajog.2015.08.034","article-title":"Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation","volume":"214","author":"Wright","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_7","unstructured":"The Fetal Medicine Foundation (2022, January 06). Stratification of Pregnancy Management 11\u201313 Weeks\u2019 Gestation. Available online: www.courses.fetalmedicine.com\/fmf\/show\/861?locale=en."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/uog.22093","article-title":"Screening for pre-eclampsia at 11\u201313 weeks\u2019 gestation: Use of pregnancy-associated plasma protein-A, placental growth factor or both","volume":"56","author":"Wright","year":"2020","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/uog.19112","article-title":"Screening for pre-eclampsia by maternal factors and biomarkers at 11\u201313 weeks\u2019 gestation","volume":"52","author":"Tan","year":"2018","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Hromadnikova, I., Kotlabova, K., and Krofta, L. (2022). First Trimester Prediction of Preterm Delivery in the Absence of Other Pregnancy-Related Complications Using Cardiovascular-Disease Associated MicroRNA Biomarkers. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073951"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hromadnikova, I., Kotlabova, K., and Krofta, L. (2022). Cardiovascular Disease-Associated MicroRNA Dysregulation during the First Trimester of Gestation in Women with Chronic Hypertension and Normotensive Women Subsequently Developing Gestational Hypertension or Preeclampsia with or without Fetal Growth Restriction. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020256"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hromadnikova, I., Kotlabova, K., and Krofta, L. (2022). First-Trimester Screening for Fetal Growth Restriction and Small-for-Gestational-Age Pregnancies without Preeclampsia Using Cardiovascular Disease-Associated MicroRNA Biomarkers. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030718"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hromadnikova, I., Kotlabova, K., and Krofta, L. (2022). Cardiovascular Disease-Associated MicroRNAs as Novel Biomarkers of First-Trimester Screening for Gestational Diabetes Mellitus in the Absence of Other Pregnancy-Related Complications. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810635"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"(2018). ACOG Committee Opinion No. 743. Low-Dose Aspirin Use During Pregnancy. Obstet. Gynecol., 132, e44\u2013e52.","DOI":"10.1097\/AOG.0000000000002708"},{"key":"ref_15","unstructured":"National Institute for Health and Care Excellence (2022, January 06). Hypertension in Pregnancy: Diagnosis and Management. Available online: www.nice.org.uk\/guidance\/ng133."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.thromres.2015.11.032","article-title":"Gestational hypertension, preeclampsia and intrauterine growth restriction induce dysregulation of cardiovascular and cerebrovascular disease associated microRNAs in maternal whole peripheral blood","volume":"137","author":"Hromadnikova","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Hromadnikova, I., Kotlabova, K., and Krofta, L. (2021). Association Analysis in Young and Middle-Aged Mothers-Relation between Expression of Cardiovascular Disease Associated MicroRNAs and Abnormal Clinical Findings. J. Pers Med., 11.","DOI":"10.3390\/jpm11010039"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijcard.2019.05.036","article-title":"Postpartum profiling of microRNAs involved in pathogenesis of cardiovascular\/cerebrovascular diseases in women exposed to pregnancy-related complications","volume":"291","author":"Hromadnikova","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hromadnikova, I., Kotlabova, K., Dvorakova, L., and Krofta, L. (2020). Diabetes Mellitus and Cardiovascular Risk Assessment in Mothers with a History of Gestational Diabetes Mellitus Based on Postpartal Expression Profile of MicroRNAs Associated with Diabetes Mellitus and Cardiovascular and Cerebrovascular Diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072437"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"RESEARCH0034","DOI":"10.1186\/gb-2002-3-7-research0034","article-title":"Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes","volume":"3","author":"Vandesompele","year":"2002","journal-title":"Genome Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/0002-9378(95)91377-7","article-title":"Risk factors for the development of preterm premature rupture of the membranes after arrest of preterm labor","volume":"173","author":"Guinn","year":"1995","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/1933719108329095","article-title":"Inflammation and pregnancy","volume":"16","author":"Challis","year":"2009","journal-title":"Reprod. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jri.2010.11.003","article-title":"Pharmacological inhibition of inflammatory pathways for the prevention of preterm birth","volume":"88","author":"Keelan","year":"2011","journal-title":"J. Reprod. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/ije\/22.3.495","article-title":"Risks for premature rupture of amniotic membranes","volume":"22","author":"Ekwo","year":"1993","journal-title":"Int. J. Epidemiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1055\/s-2007-999527","article-title":"Risk factors for preterm premature rupture of the fetal membranes","volume":"7","author":"Hadley","year":"1990","journal-title":"Am. J. Perinatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(80)90674-1","article-title":"Causes and consequences of premature rupture of fetal membranes","volume":"1","author":"Naeye","year":"1980","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.ajpath.2014.02.011","article-title":"Histological evidence of oxidative stress and premature senescence in preterm premature rupture of the human fetal membranes recapitulated in vitro","volume":"184","author":"Menon","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/aji.12220","article-title":"Expression of 8-oxoguanine glycosylase in human fetal membranes","volume":"72","author":"Menon","year":"2014","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Menon, R., Yu, J., Basanta-Henry, P., Brou, L., Berga, S.L., Fortunato, S.J., and Taylor, R.N. (2013). Short fetal leukocyte telomere length and preterm prelabor rupture of the membranes. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0031136"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3389\/fimmu.2018.00993","article-title":"Meta-Analysis of Maternal and Fetal Transcriptomic Data Elucidates the Role of Adaptive and Innate Immunity in Preterm Birth","volume":"9","author":"Vora","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/1933719111398150","article-title":"Effects of progesterone treatment on expression of genes involved in uterine quiescence","volume":"18","author":"Soloff","year":"2011","journal-title":"Reprod. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1210\/jc.2002-021862","article-title":"Human myometrial quiescence and activation during gestation and parturition involve dramatic changes in expression and activity of particulate type II (RII alpha) protein kinase A holoenzyme","volume":"88","author":"MacDougall","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/10\/2591\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:54:57Z","timestamp":1760144097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/10\/2591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,15]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["biomedicines10102591"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10102591","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,15]]}}}